Literature DB >> 10951245

Evidence for involvement of the epidermal platelet-activating factor receptor in ultraviolet-B-radiation-induced interleukin-8 production.

N B Countryman1, Y Pei, Q Yi, D F Spandau, J B Travers.   

Abstract

Ultraviolet B radiation has been shown to generate cutaneous inflammation in part through inducing oxidative stress and cytokine production in human keratinocytes. Amongst the proinflammatory cytokines synthesized in response to ultraviolet B radiation is the potent chemoattractant interleukin-8. Though the lipid mediator platelet-activating factor (PAF) is synthesized in response to oxidative stress, and keratinocytes express PAF receptors linked to cytokine biosynthesis, it is not known whether PAF is involved in ultraviolet-B-induced epidermal cell cytokine production. These studies examined the role of the PAF system in ultraviolet-B-induced epidermal cell interleukin-8 biosynthesis using a novel model system created by retroviral-mediated transduction of the PAF-receptor-negative human epidermal cell line KB with the human PAF receptor. Treatment of PAF-receptor-expressing KB cells with the metabolically stable PAF receptor agonist carbamoyl-PAF resulted in increased interleukin-8 mRNA and protein, indicating that activation of the epidermal PAF receptor was linked to interleukin-8 production. Ultraviolet B irradiation of PAF-receptor-expressing KB cells resulted in significant increases in both interleukin-8 mRNA and protein in comparison to ultraviolet-B-treated control KB cells. Pretreatment with PAF receptor antagonists inhibited both carbamoyl-PAF-induced and ultraviolet-B-induced interleukin-8 production in the PAF-receptor-positive cells, but not in control KB cells. Similarly, treatment of the PAF-receptor-expressing primary cultures of human keratinocytes or the human epidermal cell line A-431 with carbamoyl-PAF or ultraviolet B radiation resulted in interleukin-8 production that was partially inhibited by PAF receptor antagonists. These studies suggest that the epidermal PAF receptor may be a pharmacologic target for ultraviolet B radiation in skin and thus may act to augment ultraviolet-B-mediated production of cytokines such as interleukin-8.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951245     DOI: 10.1046/j.1523-1747.2000.00058.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.

Authors:  Peter Wolf; Dat X Nghiem; Jeffrey P Walterscheid; Scott Byrne; Yumi Matsumura; Yasuhiro Matsumura; Cora Bucana; Honnavara N Ananthaswamy; Stephen E Ullrich
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis.

Authors:  Ravi P Sahu; Amal A Kozman; Yongxue Yao; Sonia C DaSilva; Samin Rezania; Kellie C Martel; Simon J Warren; Jeffrey B Travers; Raymond L Konger
Journal:  Carcinogenesis       Date:  2012-01-04       Impact factor: 4.944

4.  Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Authors:  Vladislava O Melnikova; Krishnakumar Balasubramanian; Gabriel J Villares; Andrey S Dobroff; Maya Zigler; Hua Wang; Frederik Petersson; Janet E Price; Alan Schroit; Victor G Prieto; Mien-Chie Hung; Menashe Bar-Eli
Journal:  J Biol Chem       Date:  2009-08-24       Impact factor: 5.157

5.  Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists.

Authors:  Ravi P Sahu; Irina Petrache; Mary J Van Demark; Badri M Rashid; Jesus A Ocana; Yuxuan Tang; Qiaofang Yi; Matthew J Turner; Raymond L Konger; Jeffrey B Travers
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

6.  Transient receptor potential vanilloid 4 (TRPV4) is downregulated in keratinocytes in human non-melanoma skin cancer.

Authors:  Camilla Fusi; Serena Materazzi; Daiana Minocci; Vincenza Maio; Teresa Oranges; Daniela Massi; Romina Nassini
Journal:  J Invest Dermatol       Date:  2014-03-18       Impact factor: 8.551

7.  Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists.

Authors:  Ravi P Sahu; Matheus Ferracini; Jeffrey B Travers
Journal:  Mediators Inflamm       Date:  2015-04-02       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.